MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Lannett Company Cash and Cash Equivalents 2011-2026 | LCI
Annual Cash and Cash Equivalents Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.9 M | 93.3 M | 144 M | 140 M | 98.6 M | 118 M | 225 M | 200 M | 106 M | 42.7 M | 22.6 M | 5.28 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 225 M | 5.28 M | 107 M |
Quarterly Cash and Cash Equivalents Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.5 M | 55.8 M | 77.9 M | 87.9 M | 106 M | 98.6 M | 105 M | 98.3 M | 93.3 M | 34.2 M | 109 M | 34.2 M | 109 M | 119 M | 101 M | 119 M | 101 M | 164 M | 150 M | 164 M | 150 M | 140 M | 92.5 M | 140 M | 92.5 M | 247 M | 242 M | 247 M | 242 M | 179 M | 208 M | 179 M | 208 M | 171 M | 137 M | 171 M | 137 M | 94.4 M | 35.7 M | 94.4 M | 35.7 M | 31.5 M | 26.4 M | 31.5 M | 26.4 M | 20 M | 17.5 M | 19.9 M | 17.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 247 M | 17.5 M | 110 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
Harrow Health
HROW
|
72.9 M | $ 34.83 | -0.87 % | $ 1.28 B | USA |
 |
Assertio Holdings
ASRT
|
10.2 M | $ 18.91 | -1.82 % | $ 121 M | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 3.05 | -1.61 % | $ 42.9 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B |  France |
 |
OrganiGram Holdings
OGI
|
24.6 M | $ 1.37 | -1.09 % | $ 402 M |  Canada |
 |
Organogenesis Holdings
ORGO
|
136 M | $ 2.34 | 4.24 % | $ 308 M | USA |
 |
Pacira BioSciences
PCRX
|
277 M | $ 22.47 | 0.88 % | $ 1.04 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Sundial Growers
SNDL
|
252 M | $ 1.33 | -0.75 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 2.19 | -5.81 % | $ 2.72 M | USA |
 |
Bausch Health Companies
BHC
|
947 M | $ 5.22 | -3.51 % | $ 1.9 B | Canada |
 |
Tilray
TLRY
|
207 M | $ 6.53 | -1.95 % | $ 4.04 B | Canada |
 |
Aurora Cannabis
ACB
|
138 M | $ 3.39 | -1.6 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 0.99 | -2.67 % | $ 106 M | Canada |
 |
Veru
VERU
|
24.9 M | $ 2.48 | 3.33 % | $ 334 M | USA |
 |
Viatris
VTRS
|
992 M | $ 13.29 | -0.93 % | $ 16 B | USA |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
53.8 M | $ 4.04 | -3.0 % | $ 260 M | USA |
 |
Emergent BioSolutions
EBS
|
112 M | $ 7.78 | -3.95 % | $ 398 M | USA |
 |
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | USA |
 |
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
2.45 M | $ 0.7 | -3.93 % | $ 3.02 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
3.5 M | $ 6.64 | -3.84 % | $ 262 M | USA |
 |
Rockwell Medical
RMTI
|
10.7 M | $ 0.95 | -1.55 % | $ 34.2 M | USA |
 |
SCYNEXIS
SCYX
|
21.3 M | $ 0.96 | 4.54 % | $ 47.9 M | USA |
 |
Solid Biosciences
SLDB
|
59.9 M | $ 7.5 | -3.1 % | $ 656 M | USA |
 |
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
345 K | $ 0.61 | -0.21 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
7.48 M | $ 2.05 | -6.72 % | $ 23.7 M | USA |